659 related articles for article (PubMed ID: 18645193)
1. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G; Reid AH; Yap TA; Raynaud F; Dowsett M; Settatree S; Barrett M; Parker C; Martins V; Folkerd E; Clark J; Cooper CS; Kaye SB; Dearnaley D; Lee G; de Bono JS
J Clin Oncol; 2008 Oct; 26(28):4563-71. PubMed ID: 18645193
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
4. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
6. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Ang JE; Olmos D; de Bono JS
Br J Cancer; 2009 Mar; 100(5):671-5. PubMed ID: 19223900
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
[TBL] [Abstract][Full Text] [Related]
8. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Efstathiou E; Titus M; Tsavachidou D; Tzelepi V; Wen S; Hoang A; Molina A; Chieffo N; Smith LA; Karlou M; Troncoso P; Logothetis CJ
J Clin Oncol; 2012 Feb; 30(6):637-43. PubMed ID: 22184395
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
Attard G; Reid AH; Olmos D; de Bono JS
Cancer Res; 2009 Jun; 69(12):4937-40. PubMed ID: 19509232
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
13. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
Antonarakis ES; Eisenberger MA
Nat Clin Pract Oncol; 2009 Jan; 6(1):12-3. PubMed ID: 18957947
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
[TBL] [Abstract][Full Text] [Related]
15. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
Yin L; Hu Q
Nat Rev Urol; 2014 Jan; 11(1):32-42. PubMed ID: 24276076
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
17. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
Francini E; Fiaschi AI; Petrioli R; Francini F; Bianco V; Perrella A; Paganini G; Laera L; Roviello G
Anticancer Drugs; 2014 Apr; 25(4):472-7. PubMed ID: 24394473
[TBL] [Abstract][Full Text] [Related]
20. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
